sonst denkt ihr ich schreibe nur über positives. na ja so kanns auch gehen.
darum augen auf und nicht zu euphorisch werden.
RESEARCH ALERT-SuperGen cut to hold from strong buy
THURSDAY, AUGUST 31, 2000 10:45 AM
- Reuters
NEW YORK, Aug 31 (Reuters) - Prudential Securities analyst Peter Drake on Thursday cut his investment rating on drug company SuperGen (NASDAQ NM:SUPG) to hold from strong buy.
-- Shares of SuperGen, which specialises in cancer and blood disorders, were off 25 percent, or 7-3/16, to 20-1/2, making it the No. 3 percentage loser in early Nasdaq trade.
-- Drake wrote in research report, "We are downgrading SuperGen...based on growing concerns over the clinical progress of lead compound Rubitecan, the company's oral anti-tumour candidate for pancreatic cancer and the primary force behind our valuation of SUPG shares."
-- said Rubitecan is in late-stage trials designed to include a total of 1,800 patients.
-- said that "our previous assumptions were predicated on a Q4' 00 Phase III trial completion, a filing for marketing approval in submission in Q1/Q2 of 2001, and approval in the second half of 2001."
-- "After discussions with various industry sources, we now expect the trial to be significantly delayed. We believe that the company will not be able to complete enrollment until Q2' 01 and will not submit its NDA until Q4' 01," Drake said.
-- "By our estimates, this means a Q3' 02 approval and a Q4' 02 launch."
-- said delay appears to stem from significant issues in managing the trial. "Specifically, we understand that physicians are having difficulty in keeping patients within the protocol parameters and that the trial is suffering from an overall lack of stringent monitoring," Drake wrote.
-- said management has indicated that as many as 10-15 percent of the patients are currently ineligible for study inclusion due to protocol violations.
-- "Adding to this general uncertainty, we understand from industry contacts that partner Abbott Laboratories (NYSE:ABT) is concerned over the progress of the trial. SUPG management confirmed this with us yesterday."
darum augen auf und nicht zu euphorisch werden.
RESEARCH ALERT-SuperGen cut to hold from strong buy
THURSDAY, AUGUST 31, 2000 10:45 AM
- Reuters
NEW YORK, Aug 31 (Reuters) - Prudential Securities analyst Peter Drake on Thursday cut his investment rating on drug company SuperGen (NASDAQ NM:SUPG) to hold from strong buy.
-- Shares of SuperGen, which specialises in cancer and blood disorders, were off 25 percent, or 7-3/16, to 20-1/2, making it the No. 3 percentage loser in early Nasdaq trade.
-- Drake wrote in research report, "We are downgrading SuperGen...based on growing concerns over the clinical progress of lead compound Rubitecan, the company's oral anti-tumour candidate for pancreatic cancer and the primary force behind our valuation of SUPG shares."
-- said Rubitecan is in late-stage trials designed to include a total of 1,800 patients.
-- said that "our previous assumptions were predicated on a Q4' 00 Phase III trial completion, a filing for marketing approval in submission in Q1/Q2 of 2001, and approval in the second half of 2001."
-- "After discussions with various industry sources, we now expect the trial to be significantly delayed. We believe that the company will not be able to complete enrollment until Q2' 01 and will not submit its NDA until Q4' 01," Drake said.
-- "By our estimates, this means a Q3' 02 approval and a Q4' 02 launch."
-- said delay appears to stem from significant issues in managing the trial. "Specifically, we understand that physicians are having difficulty in keeping patients within the protocol parameters and that the trial is suffering from an overall lack of stringent monitoring," Drake wrote.
-- said management has indicated that as many as 10-15 percent of the patients are currently ineligible for study inclusion due to protocol violations.
-- "Adding to this general uncertainty, we understand from industry contacts that partner Abbott Laboratories (NYSE:ABT) is concerned over the progress of the trial. SUPG management confirmed this with us yesterday."
